An open label study to assess the safety and effect on disease activity of MabThera in patients with active rheumatoid arthritis who have had an inadequate response to prior treatment with DMARDs and/or one anti-TNF alpha agent.

Trial Profile

An open label study to assess the safety and effect on disease activity of MabThera in patients with active rheumatoid arthritis who have had an inadequate response to prior treatment with DMARDs and/or one anti-TNF alpha agent.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Jul 2012 Actual patient number changed from 196 to 215 as reported by ClinicalTrials.gov.
    • 21 May 2012 Actual patient number changed from 195 to 196 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top